Status:
COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I
Lead Sponsor:
St. Louis University
Collaborating Sponsors:
Washington University School of Medicine
Conditions:
Diabetes Mellitus, Type 2
Metformin Adverse Reaction
Eligibility:
All Genders
40-70 years
Phase:
EARLY_PHASE1
Brief Summary
Metformin is associated with a high degree of gastrointestinal intolerance, which limits the effective use of the medication. It is proposed to be an inhibitor of liver mitochondrial glycerophosphate ...
Detailed Description
Metformin is the primary drug of choice for management of type 2 diabetes mellitus. Most recent evidence suggest that the drug is a noncompetitive inhibitor of mitochondrial glycerophosphate dehydroge...
Eligibility Criteria
Inclusion
- Diabetes mellitus
- Tolerance to meformin
- Intolerance to metformin
Exclusion
- Exclusion: Pregnant or nursing mothers
- Those not competent to provide informed consent
- Known systemic allergy (not intolerance) to metformin
- Congestive heart failure NYHA class III-IV
- Renal impairment,EGFRr\<45ml/min
- Liver cirrhosis
Key Trial Info
Start Date :
October 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 27 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03445702
Start Date
October 15 2018
End Date
October 27 2020
Last Update
October 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Louis University
St Louis, Missouri, United States, 63110